Grants and Contributions:
Title:
Prader-Willi syndrome - therapy development.
Agreement Number:
934003
Agreement Value:
$300,000.00
Agreement Date:
Jul 15, 2019 - Oct 30, 2020
Description:
Chemical manufacturing process scale-up and optimization of API as well as formulation development and in vivo confirmation.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Montreal, Quebec, CA H3B 2B6
Reference Number:
172-2019-2020-Q2-934003
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
821124369
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 105 days.
Amendment Date
Jul 6, 2020
Recipient's Legal Name:
Inversago Pharma Inc
Federal Riding Name:
Ville-Marie--Le Sud-Ouest--Île-des-Soeurs
Federal Riding Number:
24077
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
54171
Amendments: